Etrials Pays $500K to Terminate Agreement with BioClinica

Wednesday, June 3, 2009 07:00 AM

Only days after BioClinica increased its purchase offer to acquire etrials Worldwide and the two companies agreed to proceed with their acquisition agreement, that agreement has been terminated.

BioClinica increased its purchase offer last week after eClinical vendor etrials received an unsolicited offer from another company. etrials has now entered into a new merger agreement with that company, now identified as Merge Healthcare, at a cost of $500,000, plus reasonable out-of-pocket expenses,  to terminate the agreement with BioClinica.

"We have decided it would not be in the best interest of our shareholders to pursue this acquisition further. Although we are disappointed with the outcome, we will continue to actively look for other acquisitions that would add value and expand our eClinical service offerings," said BioClinica president and CEO Mark Weinstein in a company statement.

Under the terms of the acquisition agreement with Merge, a health IT solutions provider based in Milwaukee, Wisc., the sale will be consummated through a tender offer for all of the outstanding shares of etrials stock. The Merge tender offer consists of a mix of $0.80 in cash and 0.3448 shares of Merge common stock for each share of etrials common stock, representing an aggregate value of $1.70 per share. According to published reports, the sale price may be as much as $20 million.

The transaction is expected to close at the end of the third quarter.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 2

Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity

FDA action plan seeks to close gap in women and minority patient representation in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs